Entropy NeurodynamicsTYPTF -45.63% EBIT per Share is $-0.00 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 1,181 Biotechnology companies, Entropy Neurodynamics ranks better than 94.33% on this metric.
Entropy Neurodynamics's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 71.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 36.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Entropy Neurodynamics's EBIT per Share or its related term are showing as below:
TYPTF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -28.9 Med: 13.4 Max: 71.4
Current: 71.4
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Entropy Neurodynamics was 71.40% per year. The lowest was -28.90% per year. And the median was 13.40% per year.
TYPTF's 3-Year EBIT Growth Rate is ranked better than 94.33% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs TYPTF: 71.40
Entropy Neurodynamics (OTCPK:TYPTF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Entropy Neurodynamics EBIT per Share Related Terms
Entropy Neurodynamics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Entropy Neurodynamics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entropy Neurodynamics (TYPTF) has a EBIT per Share of $-0.00 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Entropy Neurodynamics and its competitors. According to the industry distribution chart, Entropy Neurodynamics ranks #67 out of 1181 companies in the Biotechnology industry, placing it in the top 5.7%.
Is Entropy Neurodynamics' EBIT per Share too high?
Entropy Neurodynamics' current EBIT per Share is $-0.00. Based on the distribution chart, Entropy Neurodynamics ranks #67 out of 1181 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Entropy Neurodynamics' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #67 out of 1181 companies for EBIT per Share. This places Entropy Neurodynamics in the top 6% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Entropy Neurodynamics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entropy Neurodynamics's current EBIT per Share is $-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12% above its estimated fair value. The current EBIT per Share is $-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current EBIT per Share is $-0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYPTF has been successfully added to your 